KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)</th>
</tr>
<tr>
<td class="label">Conductance</td>
<td>20-30 pS (in physiological conditions)</td>
</tr>
<tr>
<td class="label">Pharmacology</td>
<td>Sensitive to volatile anesthetics, certain analgesics</td>
</tr>
<tr>
<td class="label">Regulation</td>
<td>Activated by intracellular calcium, mechanical stretch</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Highly selective for K+ over Na+</td>
</tr>
<tr>
<td class="label">Dimerization</td>
<td>Homodimeric functional unit</td>
</tr>
<tr>
<td class="label">Glycosylation</td>
<td>N-linked glycosylation sites in extracellular loops</td>
</tr>
<tr>
<td class="label">pH Sensitivity</td>
<td>Modulated by extracellular protons</td>
</tr>
<tr>
<td class="label">Voltage Dependence</td>
<td>Weakly voltage dependent</td>
</tr>
<tr>
<td class="label">Channel</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">TREK-1</td>
<td>KCNK2</td>
</tr>
<tr>
<td class="label">TREK-2</td>
<td>KCNK10</td>
</tr>
<tr>
<td class="label">TRAAK</td>
<td>KCNK4</td>
</tr>
<tr>
<td class="label">TASK-1</td>
<td>KCNK3</td>
</tr>
<tr>
<td class="label">TASK-3</td>
<td>KCNK9</td>
</tr>
<tr>
<td class="label">TRESK</td>
<td>*KCNK18

KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)

Overview

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">KCNK18 — Potassium Two Pore Domain Channel Subfamily K Member 18 (TRESK)</th>
</tr>
<tr>
<td class="label">Conductance</td>
<td>20-30 pS (in physiological conditions)</td>
</tr>
<tr>
<td class="label">Pharmacology</td>
<td>Sensitive to volatile anesthetics, certain analgesics</td>
</tr>
<tr>
<td class="label">Regulation</td>
<td>Activated by intracellular calcium, mechanical stretch</td>
</tr>
<tr>
<td class="label">Selectivity</td>
<td>Highly selective for K+ over Na+</td>
</tr>
<tr>
<td class="label">Dimerization</td>
<td>Homodimeric functional unit</td>
</tr>
<tr>
<td class="label">Glycosylation</td>
<td>N-linked glycosylation sites in extracellular loops</td>
</tr>
<tr>
<td class="label">pH Sensitivity</td>
<td>Modulated by extracellular protons</td>
</tr>
<tr>
<td class="label">Voltage Dependence</td>
<td>Weakly voltage dependent</td>
</tr>
<tr>
<td class="label">Channel</td>
<td>Gene</td>
</tr>
<tr>
<td class="label">TREK-1</td>
<td>KCNK2</td>
</tr>
<tr>
<td class="label">TREK-2</td>
<td>KCNK10</td>
</tr>
<tr>
<td class="label">TRAAK</td>
<td>KCNK4</td>
</tr>
<tr>
<td class="label">TASK-1</td>
<td>KCNK3</td>
</tr>
<tr>
<td class="label">TASK-3</td>
<td>KCNK9</td>
</tr>
<tr>
<td class="label">TRESK</td>
<td>KCNK18</td>
</tr>
<tr>
<td class="label">Calcium sensitivity</td>
<td>High</td>
</tr>
<tr>
<td class="label">Mechanical sensitivity</td>
<td>Moderate</td>
</tr>
<tr>
<td class="label">Tissue expression</td>
<td>Sensory</td>
</tr>
<tr>
<td class="label">Disease relevance</td>
<td>Migraine</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>

KCNK18 encodes TRESK (Two-pore domain potassium channel subfamily K member 18), a member of the two-pore domain potassium channel (K2P) family. TRESK is a background potassium channel that contributes to the resting membrane potential and regulates neuronal excitability. It is predominantly expressed in sensory neurons, including trigeminal ganglion neurons and dorsal root ganglion neurons, where it plays a critical role in pain signaling and migraine pathophysiology[@czeschik2010][@coetzee2010].

TRESK has attracted significant attention due to its direct involvement in familial migraine. The discovery of dominant mutations in KCNK18 that cause migraine with aura established a direct link between a specific ion channel and migraine pathogenesis. This finding has opened new therapeutic avenues for migraine treatment and has deepened our understanding of the neurobiology of pain and headache disorders[@li2013][@cortes2016].

Gene Structure and Evolution

Genomic Organization

The KCNK18 gene is located on chromosome 10q26.3 and consists of 4 exons that encode a protein of 380 amino acids. The gene is evolutionarily conserved, with orthologs identified in mammals, birds, and fish.

The gene structure includes:

• Promoter region: Contains elements for neuronal-specific expression
• Alternative splicing: Generates multiple transcript variants
• Conservation: High conservation of pore-forming regions across species

Evolutionary Conservation

TRESK shows significant evolutionary conservation:

• K2P channels evolved early in eukaryotic evolution
• TRESK is conserved from fish to humans
• The pore domain and selectivity filter are highly preserved
• Splice variants show species-specific regulation

Splice Variants

Multiple KCNK18 transcript variants have been identified:

• Variant 1 (canonical): Full-length TRESK channel
• Variant 2: Alternative N-terminus
• Variant 3: Truncated form with altered function

Protein Structure and Function

Domain Architecture

TRESK is a potassium-selective ion channel with characteristic K2P structure:

Channel Properties

Gating Mechanisms

TRESK exhibits unique gating properties:

• Background/leak current: Contributes to resting membrane potential
• Calcium sensitivity: Activated by increased intracellular Ca2+
• Volatile anesthetic sensitivity: Activated by isoflurane, sevoflurane
• Mechanical sensitivity: Responds to membrane stretch
• pH sensitivity: Modulated by extracellular protons

Single-Channel Properties

TRESK single-channel behavior[@baker2005]:

Conductance:

• Single-channel conductance: 26-30 pS in symmetric K+
• Linear I-V relationship
• Temperature coefficient (Q10)

• Open state lifetime: 10-50 ms
• Burst behavior
• Clustering at high expression

Voltage Dependence

TRESK voltage gating:

Characteristics:

• Weak voltage dependence
• Primarily voltage-independent "leak" channel
• Modest activation at depolarized potentials

• Contributes to background current
• Maintains resting potential
• Limits excitability

Ion Selectivity and Permeation

TRESK channels exhibit remarkable ion selectivity[@coetzee2010]:

Selectivity Filter:

• Highly selective for K+ over Na+ (~10:1 selectivity)
• Pore architecture determines ion discrimination
• Conservation of selectivity sequence across species

• Single-channel conductance: 20-30 pS in physiological K+
• Linear current-voltage relationship
• Temperature dependence of conductance

Post-Translational Modifications

TRESK regulation by covalent modifications:

Phosphorylation:

• PKC-mediated phosphorylation
• Modulation of channel activity
• Calcium-dependent pathways

• N-linked glycosylation in extracellular loops
• Membrane trafficking effects
• Cell surface expression

Expression and Localization

Tissue Distribution

TRESK shows selective expression in excitable tissues:

High expression:

• Trigeminal ganglion: Primary site for migraine pain processing
• Dorsal root ganglion: Sensory processing, pain signaling
• Spinal cord: Dorsal horn neurons
• Brain: Various regions including cortex, thalamus

• Heart: Cardiac myocytes
• Testis: Germ cells

Brain Region Expression

Within the nervous system, TRESK is expressed in:

Role in Neurological Diseases

Clinical Manifestations

Familial Migraine

KCNK18 mutation phenotypes[@li2013]:

Penetrance:

• Age-dependent expression
• Variable severity
• Gender influences

• Migraine with aura
• Attack frequency
• Trigger sensitivity

Sporadic Cases

Somatic and rare variants:

De novo mutations:

• New mutations in affected individuals
• Gonadal mosaicism
• Parental carrier testing

• Multiple variant inheritance
• Complex disease presentation

Pathophysiological Mechanisms

Neuronal Hyperexcitability

How TRESK loss causes disease[@dabagh2019]:

Resting Membrane Potential:

• Depolarization due to reduced K+ current
• Lowered action potential threshold
• Increased firing probability

• Amplified synaptic inputs
• Enhanced temporal summation
• Spatial summation changes

Cortical Spreading Depression

TRESK in CSD[@cortes2016]:

Mechanism:

• Propagating depolarization wave
• Hyperexcitability triggers CSD
• Role in migraine aura

• CSD prevention strategies
• Neuronal stabilization
• Vascular changes

Translational Research

Biomarker Development

TRESK as a biomarker[@muir2016]:

Peripheral Markers:

• Blood cell expression
• RNA measurements
• Protein detection

• Disease severity
• Treatment response
• Prognostic value

Gene Therapy

TRESK gene therapy approaches[@wang2018]:

Viral Vectors:

• AAV serotypes
• Neuronal targeting
• Expression control

• Mutation correction
• Promoter activation
• Allele-specific editing

Therapeutic Potential

TRESK-based therapies under development:

Activators:

• Restore channel function
• Reduce neuronal hyperexcitability
• Decrease migraine frequency

• Viral delivery of wild-type KCNK18
• CRISPR-based mutation correction
• Promoter engineering for expression

Future Directions

Research Priorities

Key questions for TRESK research:

Emerging Technologies

New approaches:

Optogenetics:

• Light-controlled channels
• In vivo manipulation
• Circuit mapping

• Patient-derived neurons
• Disease modeling
• Drug screening

Summary

KCNK18 (TRESK) is a critical two-pore domain potassium channel predominantly expressed in sensory neurons. Loss-of-function mutations cause familial migraine with aura, establishing TRESK as a causal migraine gene. Beyond migraine, TRESK plays roles in epilepsy, neuropathic pain, and neuroprotection. Its unique gating properties—calcium sensitivity, mechanical responsiveness, and anesthetic activation—make it an intriguing drug target. Understanding TRESK biology offers opportunities for developing novel migraine and pain therapies.

Animal Model Studies

TRESK Knockout Mice

Genetic loss-of-function studies:

Behavioral Phenotypes:

• Increased susceptibility to seizures
• Altered pain thresholds
• Migraine-like behaviors under stress

• Neuronal hyperexcitability in DRG neurons
• Enhanced cortical spreading depression
• Altered thalamic burst firing

Disease Models

TRESK in pathological contexts:

Migraine Models:

• Cortical spreading depression induction
• Trigeminal nociception testing
• Stress-induced headache

• Neuropathic pain induction
• Inflammatory pain responses
• Post-operative pain

Therapeutic Outlook

Clinical Development Pipeline

Current status of TRESK-targeted therapies:

Early Discovery:

• High-throughput screening for activators
• Structure-based drug design
• Natural product screening

• Lead optimization
• In vivo efficacy models
• Safety pharmacology

Challenges and Opportunities

TRESK drug development considerations:

Challenges:

• Achieving CNS penetration
• Selectivity over related channels
• Long-term safety profile

• Genetic validation supports target
• Clear patient stratification possible
• Large unmet need in migraine

Pharmacological Modulation

TRESK Activators

Current activators under investigation:

Volatile Anesthetics:

• Isoflurane activates TRESK
• Sevoflurane effects
• Desflurane modulation

• Pyrazole derivatives
• Acetylcholine analogs
• Natural product activators

TRESK Inhibitors

Blocking TRESK function:

Applications:

• Cancer therapy potential
• Specific pain conditions
• Research tools

• Bithionol and analogs
• Quaternary ammonium compounds
• Peptide toxins

Clinical Correlations

Patient Phenotypes

Clinical presentation patterns:

Migraine with Aura:

• Attack frequency varies
• Visual aura most common
• Trigger sensitivity

• Chronic daily headache
• Trigeminal neuralgia
• Post-herpetic neuralgia

Response to Treatment

Therapeutic implications:

Standard Therapies:

• Triptan responsiveness
• Preventive medication effects
• Acute vs. chronic treatment

• Expected efficacy profile
• Side effect predictions
• Combination strategies

References

• Reduced TRESK current leads to neuronal hyperexcitability
• Trigeminal ganglion neurons become more excitable
• Promotes cortical spreading depression (CSD)
• Facilitates trigeminovascular activation

• TRESK activators may provide migraine relief
• Gene therapy approaches to restore channel function
• Small molecule modulators under development

Epilepsy

TRESK contributes to seizure susceptibility[@kohling2020][@dabagh2019]:

1. Neuronal Excitability

• Background K+ currents limit excitability
• Loss of TRESK function increases seizure risk
• Mutations may predispose to epilepsy

• K2P channels as drug targets for epilepsy
• TRESK modulators may reduce seizure frequency

Neuropathic Pain

TRESK plays a role in pain processing[@peng2018][@ying2019][@gu2019]:

1. Sensory Neuron Function

• TRESK regulates sensory neuron excitability
• Contributes to resting membrane potential
• Modulates nociceptive signaling

• Reduced TRESK function in chronic pain states
• Potential for analgesic drug development

• TRESK in satellite glial cells around DRG neurons
• Modulates neuron-glia communication
• Contributes to chronic pain maintenance

Neuroprotection

TRESK may provide neuroprotective effects[@nematian2017][@tang2021]:

• Background K+ currents protect against excitotoxicity
• May limit ischemic damage
• Role in metabolic stress response
• Potential in traumatic brain injury

Interaction Network

Protein-Protein Interactions

TRESK interacts with various cellular proteins:

• Calmodulin: Calcium-dependent regulation
• Protein kinases: PKA, PKC modulation

• Ankyrin G: Membrane localization
• Filamin A: Cytoskeletal interactions

Signaling Pathways

TRESK is regulated by multiple signaling pathways:

• Ca2+/calmodulin pathway: Direct activation
• PKC pathway: Phosphorylation-dependent modulation
• Mechanical stretch: Activation through membrane deformation

Therapeutic Implications

Drug Development

TRESK is a promising drug target[@enyong2016][@ma2016]:

1. Activators

• Small molecules that enhance TRESK current
• Could reduce neuronal excitability in migraine
• Volatile anesthetics as models

• May have utility in certain pain conditions
• Caution due to complex physiological roles

Clinical Development

Current development status:

Personalized Medicine

TRESK genotyping may guide migraine treatment:

• Identifying mutation carriers
• Predicting treatment response
• Precision medicine approaches

K2P Channel Family

Family Members

The K2P channel family includes multiple members[@coetzee2010]:

Structural Features

All K2P channels share:

• Four transmembrane segments
• Two pore domains (P1, P2)
• Intracellular N- and C-termini
• Form homodimers or heterodimers

Mechanisms of Disease

Migraine Pathogenesis

The migraine-TRESK connection involves multiple mechanisms[@wang2018]:

TRESK Mutation --> Loss of Function
|
v
Reduced K+ Current --> Neuronal Depolarization
|
v
Increased Excitability --> Trigeminal Ganglion Hyperexcitability
|
v
Cortical Spreading Depression --> Migraine Aura
|
v
Trigeminovascular Activation --> Headache

Pain Signaling

TRESK modulates pain through sensory neuron regulation[@korn2011]:

Clinical Associations

Familial Migraine

KCNK18 mutations are found in:

• Familial migraine with aura
• Sporadic migraine cases
• Hemiplegic migraine variants

Chronic Pain Conditions

TRESK dysfunction associated with:

• Chronic migraine
• Trigeminal neuralgia
• Post-herpetic neuralgia
• Diabetic neuropathy

Other Neurological Conditions

• Multiple sclerosis: TRESK in demyelination and neuropathic pain[@zhao2022]
• Traumatic brain injury: TRESK in post-traumatic headache[@cheng2023]
• Epilepsy: As noted above

Cellular Mechanisms

Resting Membrane Potential

TRESK contributes to neuronal resting membrane potential:

Background Conductance:

• Provides leak K+ conductance
• Stabilizes membrane potential at ~-70 mV
• Limits depolarization-induced excitability

• Prevents excessive neuronal firing
• Maintains proper balance of excitation/inhibition
• Protects against hyperexcitability

Calcium Signaling

TRESK regulates intracellular calcium[@czeschik2010]:

Calcium Activation:

• Direct activation by intracellular Ca2+
• Calmodulin-dependent mechanism
• Links excitability to calcium signaling

• Modulates neurotransmitter release
• Affects gene expression pathways
• Controls neuronal plasticity

Synaptic Transmission

TRESK at synapses:

Presynaptic Effects:

• Regulates release probability
• Modulates quantal content
• Affects short-term plasticity

• Controls synaptic integration
• Modulates dendritic excitability
• Influences learning and memory

Clinical Considerations

Diagnostic Approaches

Diagnosing TRESK-related conditions:

Genetic Testing:

• KCNK18 sequencing
• Variant interpretation
• Family testing

• Peripheral nerve studies
• Skin biopsy for nerve function
• Nerve conduction studies

Treatment Strategies

Managing TRESK-related disorders:

Acute Treatment:

• Standard migraine medications
• Pain management protocols
• Acute seizure control

• Lifestyle modifications
• prophylactic medications
• Avoidance of triggers

Research Methods

Key approaches for studying TRESK:

• Electrophysiology: Patch-clamp recording of currents
• Molecular biology: Mutagenesis, functional analysis
• Animal models: Knockin/knockout mice
• iPSC neurons: Patient-derived disease models
• Genetic studies: GWAS, exome sequencing

Cross-References

TRESK connects to multiple NeuroWiki pages:

• [Ion Channel Dysfunction](/mechanisms/ion-channel-dysfunction)
• [Migraine](/diseases/migraine)
• [Epilepsy](/diseases/epilepsy)
• [Neuropathic Pain](/mechanisms/neuropathic-pain)
• [Neuronal Excitability](/mechanisms/neuronal-excitability)
• [KCNK2](/genes/kcnk2)
• [KCNK9](/genes/kcnk9)
• [Trigeminal Ganglion](/brain-regions/trigeminal-ganglion)
• [Cortical Spreading Depression](/mechanisms/cortical-spreading-depression)

Future Directions

Research Priorities

Emerging Approaches

• Cryo-EM structure determination
• Patient-specific iPSC models
• High-throughput compound screening
• AAV-mediated gene delivery

Summary

KCNK18 (TRESK) is a critical two-pore domain potassium channel predominantly expressed in sensory neurons. Loss-of-function mutations cause familial migraine with aura, establishing TRESK as a causal migraine gene. Beyond migraine, TRESK plays roles in epilepsy, neuropathic pain, and neuroprotection. Its unique gating properties—calcium sensitivity, mechanical responsiveness, and anesthetic activation—make it an intriguing drug target. Understanding TRESK biology offers opportunities for developing novel migraine and pain therapies.

Comparative Channel Physiology

TRESK vs. Other K2P Channels

Distinguishing features of TRESK:

Evolutionary Perspective

TRESK conservation across species:

Mammalian:

• Human TRESK: 380 amino acids
• Mouse TRESK: Highly conserved
• Rat TRESK: 97% identity

• Zebrafish ortholog characterized
• Avian TRESK variants
• Evolutionary origins

Future Research Directions

Unresolved Questions

Key knowledge gaps:

Emerging Technologies

New research tools:

Structural Biology:

• Cryo-EM structure determination
• X-ray crystallography
• Computational modeling

• CRISPR gene editing
• AAV gene therapy
• Antisense oligonucleotides

• Optogenetic manipulation
• Fiber photometry
• In vivo calcium imaging

References